Can tirzepatide (Mounjaro) be initiated in a patient with hyperthyroidism, and what precautions are required?

Tirzepatide and Hyperthyroidism

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), but can be used cautiously in patients with other forms of hyperthyroidism after appropriate evaluation and with close monitoring. 1

Key Contraindications

The FDA label for Mounjaro (tirzepatide) explicitly states absolute contraindications related to thyroid disease 1:

• Personal or family history of medullary thyroid carcinoma (MTC) - tirzepatide causes thyroid C-cell tumors in rats, and while human relevance remains undetermined, this represents a black box warning 1
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1

These contraindications stem from preclinical findings of thyroid C-cell tumors in rodent studies, though the clinical significance in humans has not been established 1.

Non-MTC Hyperthyroidism Considerations

For patients with other forms of hyperthyroidism (Graves' disease, toxic nodular goiter, thyroiditis), tirzepatide is not explicitly contraindicated, but several important considerations apply:

Pre-Treatment Evaluation Required

• Screen for personal/family history of MTC or MEN 2 before initiating therapy 1
• Ensure hyperthyroidism is adequately controlled - the AGA guidelines note that phentermine-containing medications should not be used in patients with untreated hyperthyroidism due to concerns for arrhythmias 2
• While this specific guidance applies to sympathomimetic agents rather than GLP-1/GIP agonists, the principle of controlling thyroid disease before initiating metabolic therapies is prudent

Monitoring During Treatment

Counsel patients on symptoms of thyroid tumors including neck mass, dysphagia, dyspnea, or persistent hoarseness 1:

• A case report documented drug-induced painless biphasic thyroiditis (initial thyrotoxicosis followed by transient hypothyroidism) after two months of tirzepatide therapy in a 32-year-old woman with no prior thyroid disease 3
• The patient's thyroid function normalized two months after discontinuing tirzepatide without treatment 3
• This highlights the need for clinician awareness of potential thyroid-related adverse effects, though such cases appear rare 3

Clinical Algorithm for Initiation

Step 1: Exclude absolute contraindications

• Obtain detailed personal and family history for MTC or MEN 2 1
• If present, do not prescribe tirzepatide

Step 2: Assess thyroid status

• If hyperthyroidism is present, determine etiology (Graves', toxic nodular, thyroiditis) 2
• Ensure hyperthyroidism is treated and controlled with standard therapy (antithyroid medications, beta-blockers as needed) 2
• Check TSH and free T4 to confirm euthyroid status before initiating tirzepatide

Step 3: Initiate with standard dosing

• Begin with 2.5 mg subcutaneously once weekly 1
• Advance to 5 mg after 4 weeks, with further dose escalation in 2.5 mg increments every 4 weeks as needed for glycemic control 1

Step 4: Monitor thyroid function

• Counsel patients on thyroid tumor symptoms (neck mass, dysphagia, dyspnea, persistent hoarseness) 1
• Consider periodic thyroid function testing, particularly if symptoms develop 3
• Monitor for signs of thyroiditis (biphasic pattern of hyperthyroidism followed by hypothyroidism) 3

Important Caveats

• Gastrointestinal adverse events are dose-dependent and occur in 39%-49% of patients, with nausea and diarrhea being most common 4
• Drug discontinuation due to adverse events occurs in approximately 10% of patients on the 15 mg dose 4
• The presence of controlled hyperthyroidism does not appear to increase risk of tirzepatide-specific adverse events, though data are limited 4, 5
• Real-world safety data show injection-site reactions and dosing errors as common issues, but thyroid-related adverse events remain rare 5